Hospitalised COVID-19 Patients Cohort Study in the EuCARE Project

Condition(s) studied

Investigational drug(s) / intervention(s)

standard of care: The patient will be treated following the satndard of care in the participating units

Study summary

The WP3 hospitalized cohort in EuCARE is an observational multicentre study including collection of retrospective (historical) and prospective data from hospitalized COVID-19 patients followed at 12 clinics from 11 countries from 4 continents. In a subset of patients, peripheral blood, viral isolates and/or viral sequences are collected for analysis in WP2 with regards to neutralising antibodies, cellular immunity and SARS-CoV-2 diagnostics. Data and results from analysis of biological material will be analysed by biostatistical methods and with artificial intelligence in WP5. This analysis will focus on the impact on clinical outcome of viral variants / viral sequences as well as the vaccines used and the vaccination schedules.

Eligibility

Primary outcome measure(s)

• Severity of SARS-CoV-2 infection — through study completion, an average of 4 year
  This is currently being discussed, which classification system should be used. This will be harmonized to recommendations by the WHO/ISARIC or other source.
• In-hospital mortality — through study completion, an average of 4 year
  YYYY-MM-DD or NA if discharged alive
• ICU Admissions and Discharges — through study completion, an average of 4 year
  YYYY-MM-DD or NA if not ICU-admitted
• Rate of Invasive and Non invasive mechanical ventilation — through study completion, an average of 4 year
  Yes/No/Unknown - If yes, duration of mechanical ventilation

Trial sites (10)

More Euresist Network GEIE trials in Germany

Other trials for the same condition